Compare Nutrien Ltd (NTR) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Sana Biotechnology Inc — how do they compare? Nutrien Ltd trades at $66.39 (market cap $32.05B), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Nutrien Ltd is far larger — about 28.4× Sana Biotechnology Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| NTR | SANA | |
|---|---|---|
Market Cap | $32.05B | $1.13B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $5.92 |
52-Week Low | $53.64 | $2.68 |
Enterprise Value | $43.86B | $1.05B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $66.43, up 0.18% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating revenue expectations, driven by higher potash prices. Financials show a net income margin of 8.44% for 2025, with a P/E ratio of 13.62 indicating reasonable valuation. Recent news highlights institutional buying and dividend declarations, while cash flow trends indicate consistent operational strength amid net outflows.
Outlook remains cautiously optimistic with a consensus price target of $76.17, suggesting 14.6% upside, supported by analyst buy ratings at 60.6%. Key opportunities include structural gas arbitrage benefits and agricultural cycle recovery, but risks involve input cost pressures, volatile fertilizer demand, and earnings consistency challenges. The stock presents a value opportunity with dividend yield, though macroeconomic and sector-specific headwinds warrant monitoring.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
